Synthetic microparticles conjugated with VEGF165 improve the survival of endothelial progenitor cells via microRNA-17 inhibition

Several cell-based therapies are under pre-clinical and clinical evaluation for the treatment of ischemic diseases. Poor survival and vascular engraftment rates of transplanted cells force them to work mainly via time-limited paracrine actions. Although several approaches, including the use of solub...

Full description

Bibliographic Details
Main Author: Aday, Sezin (author)
Other Authors: Zoldan, Janet (author), Besnier, Marie (author), Carreto, Laura (author), Saif, Jaimy (author), Fernandes, Rui (author), Santos, Tiago (author), Bernardino, Liliana Inácio (author), Langer, Robert (author), Emanueli, Costanza (author), Ferreira, Lino (author)
Format: article
Language:eng
Published: 2017
Subjects:
Cell- and Tissue-Based Therapy
Cell-Derived Microparticles
Cyclin-Dependent Kinase Inhibitor p21
DNA-Binding Proteins
Endothelial Progenitor Cells
Fetal Blood
Gene Expression Regulation
Human Umbilical Vein Endothelial Cells
Humans
Ischemia
MicroRNAs
Neovascularization, Physiologic
Phosphorylation
Proto-Oncogene Proteins c-akt
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-2
Cell Survival
Online Access:http://hdl.handle.net/10316/92390
Country:Portugal
Oai:oai:estudogeral.sib.uc.pt:10316/92390

Internet

http://hdl.handle.net/10316/92390

Similar Items